# Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

> **NCT05492123** · PHASE2 · RECRUITING · sponsor: **Hospital Israelita Albert Einstein** · enrollment: 112 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms

## Interventions

- **DRUG:** Nivolumab 40 mg in 4 ml Injection
- **DRUG:** Ipilimumab 200 MG in 40 ML Injection
- **RADIATION:** Chemoradiation

## Key facts

- **NCT ID:** NCT05492123
- **Lead sponsor:** Hospital Israelita Albert Einstein
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-30
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2024-01-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05492123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05492123, "Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05492123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*